Results 31 to 40 of about 2,969,292 (313)
Frequent adaptive immune responses against arginase-1
OncoImmunology, 2018 The enzyme arginase-1 reduces the availability of arginine to tumor-infiltrating immune cells, thus reducing T-cell functionality in the tumor milieu. Arginase-1 is expressed by some cancer cells and by immune inhibitory cells, such as myeloid-derived ...
Evelina Martinenaite +9 more
doaj +1 more source
Hedgehog Signalling in Androgen Independent Prostate Cancer [PDF]
, 2008 Objectives: Androgen-deprivation therapy effectively shrinks hormone-naïve prostate cancer, both in the prostate and at sites of distant metastasis.
Bisson, Isabelle +7 more
core +1 more source
Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer [PDF]
, 2019 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel ...
Adile, Ashley A. +19 more
core +3 more sources
Technology in Cancer Research & Treatment, 2005 The prognosis of patients with some kinds of cancers whose patients are often found unresectable upon diagnosis is still dismal. In these fields, development of a new therapeutic modality is needed and gene therapy represents one promising strategy. So far, numerous cancer gene therapy clinical trials based on these principles have been carried out ...
Masato, Yamamoto, David T, Curiel
openaire +2 more sources
Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy [PDF]
, 2015 The selective and efficient drug delivery to tumor cells can remarkably improve different cancer therapeutic approaches. There are several nanoparticles (NPs) which can act as a potent drug carrier for cancer therapy.
Bahrami, B. +8 more
core +1 more source
Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy [PDF]
, 2017 Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease; the identification of novel targets and development of effective treatment strategies are urgently needed to improve patient outcomes.
Olson, Michael F. +4 more
core +1 more source
Science, 2010 Last month, the U.S. Food and Drug Administration (FDA) announced that it plans to draft new guidelines for testing and approving the use of multidrug treatments for diseases. For cancer treatment, the need for this approach and its attendant guidelines are based on an advanced understanding of the disease that has emerged from 30 years of research. If
openaire +2 more sources
Actionability classification of variants of unknown significance correlates with functional effect
npj Precision Oncology, 2023 Genomically-informed therapy requires consideration of the functional impact of genomic alterations on protein expression and/or function. However, a substantial number of variants are of unknown significance (VUS).
Amber Johnson +18 more
doaj +1 more source
Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments [PDF]
, 2016 Although adverse effects and glucocorticoid resistance cripple their chronic use, glucocorticoids form the mainstay therapy for acute and chronic inflammatory disorders, and play an important role in treatment protocols of both lymphoid malignancies and ...
Beck, Ilse +5 more
core +2 more sources
Technical Innovations & Patient Support in Radiation Oncology, 2020 Fifteen years of reported incidents were reviewed to provide insight into the effectiveness of an Incident Learning System (ISL). The actual error rate over the 15 years was 1.3 reported errors per 1000 treatment attendances.
Sandie Smith +8 more
doaj +1 more source